Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment
- Testing by Afirma GSC and Afirma XA helps reduce unnecessary surgeries and inform disease treatment - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 17, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that a review article in Cancer Cytopathology , a journal of the American Cancer
View HTML
Toggle Summary Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 10, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma ® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce
View HTML
Toggle Summary Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis
New Findings Presented at 2019 ASCO Annual Meeting SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 1, 2019-- Veracyte, Inc . (Nasdaq: VCYT) today announced new data demonstrating the potential for its Afirma ® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients
View HTML
Toggle Summary Veracyte Announces Participation in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at two upcoming investor conferences: The William Blair 39 th Annual Growth Stock Conference in Chicago
View HTML
Toggle Summary Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 23, 2019-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data demonstrating the Afirma® Xpression Atlas test’s ability to detect gene alterations that may be targeted by new treatments for medullary thyroid cancer – a rare, but aggressive
View HTML
Toggle Summary Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 20, 2019-- Veracyte, Inc . (Nasdaq: VCYT), a leading genomic diagnostics company, today announced new data demonstrating that its next-generation Percepta ® Genomic Sequencing Classifier (GSC) provides expanded lung cancer risk information that can
View HTML
Toggle Summary Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 14, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade , M.D., medical director of pulmonology. In this role, Dr. Bhorade will lead medical affairs for Veracyte’s
View HTML
Toggle Summary Veracyte to Present at the UBS Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2019-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on 
View HTML
Toggle Summary Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 7, 2019-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
View HTML
Toggle Summary Veracyte Announces Pricing of Public Offering of 5,500,000 Shares of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2019-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per share.
View HTML